Suzhou Basecare Medical (HKG:2170) obtained approval for the renewal of the registration certificate of its PGT-A kit for five years from China's National Medical Products Administration in October, a Wednesday bourse filing said.
The renewed registration certificate is valid till Feb. 20, 2030.
The PGT-A kit is used to accurately detect the DNA of blastocyst trophoblast cells and analyze the potential existence of any abnormalities of aneuploidy in embryos.
Shares of the genetic technology researching company closed nearly 10% higher on Wednesday.
Price (HKD): $2.81, Change: $+0.25, Percent Change: +9.77%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments